← Lymphatic Malformation Variant Atlas

PIK3CA Q546K

c.1636C>A NM_006218.3 PI3K-AKT transversion, gain of function

Cancer hotspot Recurrent missense variant. COSMIC COSV55873527, COSV55882350
Population · gnomAD Not observed Absent from the population database, consistent with a somatic, non-inherited driver.
ClinVar Pathogenic VCV000013657
Protein region PIK helical Residue 546 of PIK3CA. UniProt P42336
AlphaMissense likely pathogenic Pathogenicity score 0.90. Computational prediction, not clinical evidence.

Position in PIK3CA 14 catalogued

PI3K-ABD (16–105)PI3K-ABDPI3K-RBD (187–289)PI3K-RBDC2 PI3K-type (330–487)C2 PI3K-typePIK helical (517–694)PIK helicalPI3K/PI4K catalytic (765–1051)PI3K/PI4K ca…11068 aaR88QE109delE110delN345KC420RE542KE545AE545GE545KQ546KQ546RM1043IH1047LH1047R

Reported in LM · GLA

ISSVA subsetAllele fractionSources
LM 1.1-23%
GLA 1.1-23%

Bars show the reported allele-fraction range on a 0 to 50 percent axis.

Pathway and targeted therapy

Driver of the PI3K-AKT pathway. Repurposed drugs already used in the clinic for this pathway: alpelisib (PI3Kα inhibitor), sirolimus (mTOR inhibitor).

Open and recent trials (3 in vascular / lymphatic anomalies for alpelisib)

Primary sources (2)

  1. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly.
    Rodriguez-Laguna L, Agra N, Ibañez K, Ibañez K, Oliva-Molina G, Gordo G, Khurana N, Hominick D, Beato M, Colmenero I, Herranz G, Torres Canizalez JM, Rodríguez Pena R, Vallespín E, Martín-Arenas R, Del Pozo Á, Villaverde C, Bustamante A, Ayuso C, Lapunzina P, Lopez-Gutierrez JC, Dellinger MT, Martinez-Glez V. · J Exp Med · 2019
  2. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
    Blesinger H, Kaulfuß S, Aung T, Schwoch S, Prantl L, Rößler J, Wilting J, Becker J. · PLoS One · 2018

Mentioned in 200 publications indexed by Europe PMC.

Cross-references